Cover Image
市場調查報告書

神經纖維瘤(NF)治療藥的開發平台分析

Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 606433
出版日期 內容資訊 英文 128 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經纖維瘤(NF)治療藥的開發平台分析 Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
出版日期: 2018年01月01日 內容資訊: 英文 128 Pages
簡介

本報告提供神經纖維瘤(NF)治療藥的開發平台相關調查,彙整開發平台概要,促進因素及阻礙因素分析,臨床實驗階段·分子類型·投藥各途徑的開發平台趨勢,藥物簡介,競爭環境,主要企業簡介等資訊。

第1章 調查背景

  • 調查目的
  • 定義
  • 調查範圍
  • 主要的相關利益者

第2章 調查手法

  • 2次調查
  • 本調查
  • 市場規模的預測
  • 資料的三角法評估
  • 調查的前提條件

第3章 摘要整理

第4章 開發平台概要

  • 疾病概要
    • 神經纖維瘤(NF)的種類
  • 原因與症狀
  • 診斷
    • 神經纖維瘤第一型(NF1)
    • 神經纖維瘤2型(NF2)
  • 預後
  • 預防
  • 治療
  • 流行病學
  • 促進因素
  • 阻礙因素
  • NF治療藥的開發平台評估
    • 不同階段
    • 各分子類型
    • 各給藥途徑
    • 各企業

第5章 神經纖維瘤(NF)治療藥的開發平台分析:不同階段

  • 第二階段實驗
    • Selumetinib(Selumetinib)
    • Everolimus(Everolimus)
    • 泰嘉錠(Lapatinib)(Lapatinib)
    • 其他
  • 第1/2階段實驗
  • 第0相實驗
    • AR42
    • LB205
  • 臨床試驗前

第6章 臨床實驗檢討

  • NF治療藥的開發平台分析 - 各地區
  • NF治療藥的開發平台分析 - 各臨床實驗狀況

第7章 競爭情形

  • 主要企業的基準
  • SWOT分析

第8章 企業簡介

  • Recursion Pharmaceuticals Inc.
  • Array BioPharma Inc.
  • 其他的企業

第9章 附錄

  • 簡稱
  • 相關調查報告
目錄

The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.

Insights on pipeline segments

Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.

Unmet medical needs driving the neurofibromatosis therapeutics pipeline

Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.

Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis

The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) in Phase I study.

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
    • 1.3.1 Pipeline Analysis by Phase
    • 1.3.2 Pipeline Analysis by Molecule Type
    • 1.3.3 Pipeline Analysis by Route of Administration
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By industry participant
      • 2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Disease Overview
    • 4.1.1 Types of Neurofibromatosis
  • 4.2 Causes and Symptoms
  • 4.3 Diagnosis
    • 4.3.1 NF1 Diagnosis
    • 4.3.2 NF2 Diagnosis
  • 4.4 Prognosis
  • 4.5 Prevention
  • 4.6 Treatment
  • 4.7 Epidemiology
  • 4.8 Key Drivers
    • 4.8.1 XXX
  • 4.9 Key Barriers
    • 4.9.1 Overlapping of NF with Many RAS-Driven Disorders
    • 4.9.2 XXX
  • 4.10 Neurofibromatosis Therapeutics Pipeline Analysis
    • 4.10.1 Pipeline Analysis by Phase
    • 4.10.2 Pipeline Analysis by Molecule Type
    • 4.10.3 Pipeline Analysis by Route of Administration
    • 4.10.4 Pipeline Analysis by Company

Chapter 5. Neurofibromatosis (NF) Therapeutics Pipeline Analysis by Phase (2018)

  • 5.1 Phase II
    • 5.1.1 Selumetinib
      • 5.1.1.1 Clinical trial
      • 5.1.1.2 Clinical trial results
      • 5.1.1.3 Strategic development
    • 5.1.2 Everolimus
      • 5.1.2.1 Clinical trial
      • 5.1.2.2 Clinical trial results
    • 5.1.3 Lapatinib
      • 5.1.3.1 Clinical trial
      • 5.1.3.2 Clinical trial results
    • 5.1.4 XXX
      • 5.1.4.1 Clinical trial
    • 5.1.5 XXX
      • 5.1.5.1 Clinical trial
    • 5.1.6 XXX
      • 5.1.6.1 Clinical trial
    • 5.1.7 XXX
      • 5.1.7.1 Clinical trial
    • 5.1.8 XXX
      • 5.1.8.1 Clinical trial
    • 5.1.9 XXX
      • 5.1.9.1 Clinical trial
      • 5.1.9.2 Clinical trial results
    • 5.1.10 XXX
      • 5.1.10.1 Strategic development
    • 5.1.11 XXX
      • 5.1.11.1 Strategic development
    • 5.1.12 XXX
      • 5.1.12.1 Clinical trial
      • 5.1.12.2 Clinical trial results
      • 5.1.12.3 Strategic development
    • 5.1.13 XXX
      • 5.1.13.1 Clinical trial
    • 5.1.14 XXX
      • 5.1.14.1 Clinical trial
    • 5.1.15 XXX
      • 5.1.15.1 Clinical trial
  • 5.2 Phase I/II
    • 5.2.1 XXX
  • 5.3 Phase 0
    • 5.3.1 AR42
      • 5.3.1.1 Clinical trials
      • 5.3.1.2 Strategic development
    • 5.3.2 XXX
      • 5.3.2.1 Clinical trials
  • 5.4 Pre-Clinical
    • 5.4.1 LB201
      • 5.4.1.1 Strategic development
    • 5.4.2 LB205
    • 5.4.3 XXX
      • 5.4.3.1 Strategic development
    • 5.4.4 XXX
      • 5.4.4.1 Pre-Clinical result
      • 5.4.4.2 Strategic development
  • 5.5 Discovery
    • 5.5.1 Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for NF Type 2
      • 5.5.1.1 Strategic development
    • 5.5.2 XXX
    • 5.5.3 XXX
      • 5.5.3.1 Strategic development

Chapter 6. Clinical Trials Review

  • 6.1 Clinical Trials by Region
  • 6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for NF Therapeutics Pipeline
  • 7.2 SWOT Analysis of Neurofibromatosis Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Recursion Pharmaceuticals Inc.
    • 8.1.1 Business Overview
    • 8.1.2 Product and Service Offerings
  • 8.2 Array BioPharma Inc.
    • 8.2.1 Business Overview
    • 8.2.2 Product and Service Offerings
  • 8.3 Company 3
    • 8.3.1 Business Overview
    • 8.3.2 Product and Service Offerings
  • 8.4 Company 4
    • 8.4.1 Business Overview
    • 8.4.2 Product and Service Offerings
  • 8.5 Company 5
    • 8.5.1 Business Overview
    • 8.5.2 Product and Service Offerings
  • 8.6 Company 6
    • 8.6.1 Business Overview
    • 8.6.2 Product and Service Offerings
  • 8.7 Company 7
    • 8.7.1 Business Overview
    • 8.7.2 Product and Service Offerings
  • 8.8 Company 8
    • 8.8.1 Business overview
    • 8.8.2 Product and Service Offerings
  • 8.9 Company 9
    • 8.9.1 Business Overview
    • 8.9.2 Product and Service Offerings
  • 8.10 Company 10
    • 8.10.1 Business Overview
    • 8.10.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • COMPARATIVE FEATURES OF NF1, NF2 AND SCHWANNOMATOSIS
  • PIPELINE ANALYSIS OF NEUROFIBROMATOSIS THERAPEUTICS, BY COMPANY (2018)
  • DESCRIPTION OF SELUMETINIB
  • CLINICAL TRIALS OF SELUMETINIB
  • DOSE-LIMITING TOXIC EFFECTS OF SELUMETINIB AND RESPONSE EVALUATION
  • DESCRIPTION OF EVEROLIMUS
  • CLINICAL TRIALS OF EVEROLIMUS
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • DESCRIPTION OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • PHASE II STUDY DESIGN OF XXX IN CHILDREN AND ADULTS
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF XXX
  • DESCRIPTION OF AR42
  • CLINICAL TRIALS OF AR42
  • DESCRIPTION OF XXX
  • CLINICAL TRIALS OF XXX
  • DESCRIPTION OF LB201
  • DESCRIPTION OF LB205
  • DESCRIPTION OF XXX
  • DESCRIPTION OF XXX
  • DESCRIPTION OF SMALL MOLECULE TO INHIBIT HSP90-ALPHA AND TRAP1 FOR NF TYPE 2
  • DESCRIPTION OF DRUG FOR XXX
  • DESCRIPTION OF XXX
  • RECURSION PHARMACEUTICALS INC. - AT A GLANCE
  • ARRAY BIOPHARMA INC. - AT A GLANCE
  • COMPANY 3 - AT A GLANCE
  • COMPANY 4 - AT A GLANCE
  • COMPANY 5 - AT A GLANCE
  • COMPANY 6 - AT A GLANCE
  • COMPANY 7 - AT A GLANCE
  • COMPANY 8 - AT A GLANCE
  • COMPANY 9 - AT A GLANCE
  • COMPANY 10 - AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
  • TYPES OF NEUROFIBROMATOSIS
  • CLINICAL DIAGNOSIS OF NEUROFIBROMATOSIS
  • NEUROFIBROMATOSIS DRUG CANDIDATES IN DEVELOPMENT (2018)
  • NEUROFIBROMATOSIS PIPELINE SPLIT, BY MOLECULE TYPE (2018)
  • NEUROFIBROMATOSIS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)
  • MEAN PLASMA CONCENTRATION-TIME AND MEDIAN PHARMACOKINETIC RESULTS OF SELUMETINIB FOR THE THREE DOSE LEVELS
  • RESPONSE EVALUATION OF SELUMETINIB
  • INHIBITION OF KIT SIGNALING BY XXX
  • EFFECTS OF XXX ON SCF-INDUCED KIT ACTIVATION AND SIGNALING IN H526 SMALL CELL LUNG CANCER CELLS
  • EFFECTS OF XXX ON SCF-INDUCED KIT PHOSPHORYLATION IN CHO CELLS EXPRESSING WILD-TYPE KIT
  • EFFECTS OF XXX ON DEGRANULATION IN THE MAST CELL LINE LAD2
  • XXX INHIBITS SCF-INDUCED SECRETION OF TNF AND GM-CSF IN THE LAD2 MAST CELL LINE
  • CROSS-REACTIVITY WITH KIT FROM VARIOUS SPECIES
  • SUBSTANTIAL DECREASE IN MAST CELL
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING
  • SWOT ANALYSIS
Back to Top